Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat obesity and diabetes but are linked to a variety of gastrointestinal (GI) adverse events (AEs). Real-world data on GLP-1 RA-related GI AEs and outcomes are limited. This study assessed GI AEs and adverse outcomes using the US FDA Adverse Event Reporting System (FAERS). Methods: This retrospective pharmacovigilance study used the US FDA FAERS database (2007–2023). We searched GLP-1 RA medications, AEs, and adverse outcomes. Demographic, treatment indication, and AE data were collected. Descriptive analysis involved frequencies and percentages, while reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multivariate logistic regression were used to analyze GLP-1 RA-related GI AEs and outcomes. Results: From 2007 to 2023, a total of 187,757 AEs were reported with GLP-1 RAs, and 16,568 were GLP-1 RA-associated GI AEs in the US. Semaglutide was linked to higher odds of nausea (IC025: 0.151, βCoeff: 0.314), vomiting (IC025: 0.334, βCoeff: 0.495), and delayed gastric emptying (IC025: 0.342, βCoeff: 0.453). Exenatide was associated with pancreatitis (IC025: 0.601, βCoeff: 0.851) and death (ROR: 4.50, IC025: 1.101). Overall, semaglutide had a broader range of notable adverse effects; by comparison, dulaglutide and liraglutide use was associated with fewer significant GI AEs. Conclusions: Analysis of the FAERS data reveals that GLP-1 RAs, particularly semaglutide and exenatide, are significantly associated with specific GI AEs, such as nausea, vomiting, delayed gastric emptying, and pancreatitis. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety. This study demonstrated the utility of pharmacovigilance data in identifying safety signals, which can inform future pharmacoepidemiological investigations to confirm causal relationships. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The most prevalent adverse effects associated with GLP-1 RAs include gastrointestinal disturbances, such as nausea, vomiting, diarrhea, and constipation [6,7].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse drug reactions: definitions, diagnosis, and management
Edwards, I. R., & Aronson, J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02799-9 · Cited by 2,979
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023) · JAMA · doi:10.1001/jama.2023.19574 · Cited by 471
Self-citationHe, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326
Liu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258
Jensterle, M., Rizzo, M., Haluzík, M., & Janež, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02153-x · Cited by 215
Cited by
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
“The most prevalent adverse effects associated with GLP-1 RAs include gastrointestinal disturbances, such as nausea, vomiting, diarrhea, and constipation [6,7].”
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 34
“221 Dual receptor agonists targeting GLP-1 and GIP, such as tirzepatide, have also exhibited promising efficacy in diabetes management, notably in terms of weight reduction and glycemic control.”
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
“44,45 In a meta-analysis of 48 RCTs including 27,729 participants, the overall incidence of GI adverse events was reported to be 11.6%, with nausea identified as the most common symptom (21.4%).”
InfluentialAdvances in heterogeneity and classification of osteoarthritis
Huang, T., 舒建雄, Wu, Z. Z., Li, Z. A., Tuan, R. S., Ding, C., & Lu, Y. (2026) · Bone Research · doi:10.1038/s41413-026-00549-x · Cited by 10
“151 Weight loss is also associated with symptom relief of hip OA in overweight or obese patients.”
Li, M., Hu, J., Chin, Y. H., Chew, H. S. J., & Wang, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1681965 · Cited by 9
Stone, D., Playdon, M. C., Hursting, S. D., & Tan, A. C. (2026) · Obesity · doi:10.1002/oby.70176 · Cited by 7
Chen, J., Fang, Y., Liu, Y., Chen, M., & Tsai, M. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70187 · Cited by 6
“However, gastrointestinal side effects, including nausea and vomiting, may affect treat-ment adherence, especially among individuals with frailty [33].”
Ashlaw, E. F., Elfers, C., Chichura, K. S., Miranda, I. C., McGivney, A., Chepurny, O. G., Holz, G. G., Mullins, G., den Hartigh, L. J., Liu, Y., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156414 · Cited by 5
Marin, R. C., Vesa, C. M., Ţiţ, D. M., Radu, A.-F., & Bungau, G. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072988 · Cited by 4
“Lower reporting odds for metabolism-related events versus semaglutide but higher versus liraglutide underscore that metabolic reporting heterogeneity is comparator-dependent [35].”
Cai, M., Li, Y., Guo, M., Dong, H., & Cheng, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178113 · Cited by 4
Impact of GLP-1 receptor agonists on gastrointestinal function and symptoms
Frazier, R., & Hasler, W. L. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2579117 · Cited by 4
“Consequently, some suggest this agent may be less suitable for individuals with established gastrointestinal illnesses [38].”
InfluentialSoliman, A. T., Alyafei, F., Khalil, A., Kardousha, A., Ahmed, S., Alaaraj, N., & Hamed, N. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113400 · Cited by 3
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 4
GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia
Masulli, M., Tack, J. F., Esposito, G., & Sarnelli, G. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04117-9 · Cited by 3
“Real-world data indicate that up to 40–50% of patients receiving GLP-1 analogs experience gastrointestinal complaints, with nausea and vomiting among the most frequently reported adverse events [12, 13].”
Pursuing remission in type 2 diabetes: Competing strategies or complementary paths?
Koufakis, T., Sarafidis, P. A., Τσάπας, Α., & Doumas, M. N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70212 · Cited by 2
“27 However, meta-analyses of cardiovascular outcome trials have not shown an increased incidence of pancreatitis with GLP-1RA therapy compared with placebo.”
Lv, J., Zhang, S., Qu, Y., Cao, Y., Zhang, J., Dai, X., & Shi, L. S. (2026) · Health and Metabolism · doi:10.53941/hm.2026.100005 · Cited by 3
“Prince et al. (2025) conducted a real-world adverse events analysis of GLP-1RAs in the US using data retrieved from the FAERS Database [60].”
Garg, S., Qapaja, T., Hamid, O., Kaya, G., Abdel-Razeq, R. H., Alayan, D., Abu-Rumaileh, M. A., Lembo, A. J., & Nissen, S. E. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100736 · Cited by 1
Zheng, J., Qiu, C., & Zhang, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1700820 · Cited by 1
AUTOMEDICAÇÃO COM ANÁLOGOS DO GLP-1: RISCOS CLÍNICOS E O PAPEL DO FARMACÊUTICO NO USO RACIONAL
Santos, R. M. D. S., Amorim, L. V. A., Lima, L. M. S. D., Pereira, J. M., Silva, J., Felismino, R. J. A., Figueiredo, C. G., & Moura, M. A. B. F. D. (2026) · Aracê. · doi:10.56238/arev8n4-040 · Cited by 1
Anatriello, A., Liguori, V., Pentella, C., Zinzi, A., Longo, M., Caruso, P., Maiorino, M. I., Esposito, K., & Capuano, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00864-4 · Cited by 1
Fisch, S., Neugut, E. J., Cornet, N., Quigee, D., Neugut, A. I., & Freedberg, D. E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1936967 · Cited by 1
“Most prior analyses have evaluated GLP-1RAs as a therapeutic class irrespective of indication (Liu et al., 2022; Zhou et al., 2022; Osei et al., 2024), and most have focused on specific SOCs and AEs rather than comprehensively evaluating AE reporting patterns (Lu et al., 2025).”
Chang, T. I., Cluett, J., Cohen, D. L., Drawz, P. E., Hudson, J. Q., Kramer, H., Rahman, M., & Awdishu, L. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.07.006 · Cited by 1
GLP-1 RA-related gastrointestinal AEs differ between drugs
(2025) · Reactions Weekly · doi:10.1007/s40278-025-74809-y
Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
Hollstein, T. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2606-7020
“Gro-ße Gro-ße Endpunktstudien wie EMPA-REG OUTCOME (Empagliflozin) [20], CANVAS (Canagliflozin) [21] und DECLARE-TIMI 58 (Dapagli-flozin) [22] zeigten bei T2DM-Patienten mit hohem Risiko oder etablierter atherosklerotischer Herz-Kreislauf-Erkrankung (ASCVD) eine Reduktion von MACE und/oder eine signifikante Reduktion…”
Kim, H. S., Kim, M., Kim, H. S., Cho, Y. K., Jung, C. H., & Lee, W. J. (2025) · Clinical Endocrinology · doi:10.1111/cen.70078
“Notably, semaglutide and tirzepatide have higher rates of gastrointestinal adverse events, such as nausea and vomiting, which may limit their suitability in some cases [24, 26, 27].”
ADVERSE EFFECTS OF GLP-1 RECEPTOR AGONISTS: A COMPREHENSIVE APPROACH
Sapeda, N., Lusarczyk, W., Truszyńska-Zawisza, A., Gorczyca, K., Młocek, A., Romanowska, Z., & Białas, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4111
Real-world insights into antiobesity medications in an online patient community: a feasibility studyPreprint
Kalich, B. A., Cruz, M., Shaw, S. Y., Cordova, J. M., Ke, H., Mina, M. J., Chen, B., & Burton, P. (2026) · medRxiv · doi:10.64898/2026.01.26.26344623
Lange, M. G., Vickers, A., Hill, L. J., Mollan, S. P., Mitchell, J., Sinclair, A. J., & Lee, A. G. (2026) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002431
Evidências sobre os benefícios do uso racional dos agonistas do GLP-1 na prática clínica
da Silva, L. B. M., de Oliveira, M. E. S., de Lima, M. D. C. P., & de Almeida, V. S. (2026) · Revista Universitária Brasileira · doi:10.5281/zenodo.18705515
Reis, L. F., Yvamoto, E. Y., de Jesus, L. B. F., Saraiva, H. P., & Oliveira, É. S. (2026) · Revista fisio&terapia. · doi:10.69849/7wmx9h50
Chan, T. C., Brennan, J. J., Killeen, J. P., & Castillo, E. M. (2026) · Emergency Care and Medicine · doi:10.3390/ecm3030022
“Pancreatitis and biliary disease have also been reported with these medications [4,12,33].”
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Wang, L., Cao, Y., Wang, Z., Xiong, H., Xu, Y., & Ren, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1879986
Pires, A. L. J., Maroto, F. M., Ohara, G. H., Arinos, I. S., Linares, V. F., Borges, G., de Melo, R. C. C., Medeiros, L. L. C., SGORLA, G. S., & Júnior, J. A. A. (2026) · International Journal of Health and Surgical Research
Vergniory-Trueba, O., & Lobato, C. T. (2026) · Healthcare · doi:10.3390/healthcare14193355
“Given the well-established osmotic diuretic effect of SGLT2 inhibitors, these findings are biologically plausible and are consistent with the known pharmacological profile of this drug class [26,31].”
Himali, N. A., Al-Habsi, H., Mushrafi, A. A., Shidi, A. A., Abbas, A., Kindi, A. A., Sayid, H., Mohammadi, I., Subhi, A. A., & Kiyumi, M. H. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15207797
“That is consistent with trials and meta-analyses showing comparable gastrointestinal tolerability between the two agents [11,15,34], and with pharmacovigilance analyses of the FAERS database in which gastrointestinal symptoms predominate for both [35,36].”
Thawkar, S. A., Singare, S. R., & Sakle, N. S. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.105169
Asiri, A., DANIELS, R., Najim, A., Razak, H. R. A., & Mokbel, K. (2026) · Diabetology · doi:10.3390/diabetology7100200
Antonini, L. M. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n7-187
Инкретинотерапия ожирения и гормональная контрацепция: работа в одной связке
Рахимбердыевич, О. М. (n.d.) · CyberLeninK (CyberLeninka)
A Hybrid LSTM-XGBoost Model for Predicting Adverse Drug Reaction Severity in GLP-1 Receptor Agonists
Yu, J. (2026) · International Conference on Cyber-Physical Social Intelligence (ICCSI) · doi:10.1109/cpsi70510.2026.11734641
Gu, S., Yang, S., Tian, Y., Hu, C., Wen, D., & Shi, Y. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.120076
Research on Adverse Drug Reaction Signal Mining for Diabetes under Large-Scale Medical Data
张鑫尧 (2026) · International Conference on Biomedical and Intelligent Systems (IC-BIS) · doi:10.1145/3841905.3841999
Henriques, J. P., Henriques, M. J., Ribeiro, R. D. C. G., Cosentino, P. L. S., & Negrato, C. A. (2026) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-026-01275-1
Wu, D., Yang, R., Zeng, J., Bai, Z., Zhang, C., Fan, X., Zhou, X., Wu, L., Zhu, S., Akın, İ., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-06025-x
Rolak, S. C., Lunsford, T. N., Frazier, R., Harris, L. A., Yang, M., & Hasler, W. L. (2026) · Neurogastroenterology & Motility · doi:10.1111/nmo.70448
Metadata
- Authors
- Osei, S. P., Akomaning, E., Florut, T. F., Sodhi, M., Lacy, B. E., Aldhaleei, W. A., & Bhagavathula, A. S.
- Affiliations
- North Dakota State University (US)
- Simon Fraser University (CA)
- University of British Columbia (CA)
- Mayo Clinic (US)
- Corresponding author
- Bhagavathula, Akshaya Srikanth
- ORCID
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2024-12-16
- Volume
- 14
- Issue
- 24
- Pages
- 2829
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC11675942
- OpenAlex
- W4405445936
- Semantic Scholar
- 4f878ae6aa0ed713a97d219b9ad730d25faea332
- Cited by
- 38
- References
- 19
- Citations by year
- 2026: 24 · 2025: 14
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- cIRcle (University of British Columbia) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Open Collections
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, gastrointestinal adverse effects, semaglutide, exenatide, dulaglutide, liraglutide, nausea, vomiting, delayed gastric emptying, pancreatitis, drug safety, pharmacovigilance, adverse event reporting, obesity, diabetes mellitus, FDA Adverse Event Reporting System, safety signals, reporting odds ratio, proportional reporting ratio
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.